Skip to main content
. 2006 Oct 2;203(10):2263–2269. doi: 10.1084/jem.20060995

Figure 3.

Figure 3.

Priming of new, naive antiviral CD8 T cells during persistent infection. (A) Partial bone marrow chimerism protocol. (B) Mice infected by PyV 84 d earlier were either injected with splenocytes or bone marrow cells or treated with busulfan and injected with bone marrow cells the next day (n = 3–8 mice). Spleens were analyzed 42 d later and assessed for chimerism. Each plot contains 105 events, and values represent the percentage of lymphocytes within the indicated regions. (C) Mice infected by PyV 115 d earlier were treated with busulfan and injected with bone marrow cells as in A. Organs were analyzed for Db-LT359 tetramer+ CD8 T cells 51 d after cell transfer. Plots are gated on donor or host CD8 T cells, and values indicate the percentage of tetramer+ cells. 10 and 8% of tetramer+ cells are of donor origin in the spleen and lung, respectively. (D) Mice infected by LCMV clone 13 120 d earlier were treated with busulfan and received bone marrow cells as in A. Organs were analyzed for Db-gp276 tetramer+ CD8 T cells 48 d after cell transfer (n = 6). Plots are gated on host or donor CD8 T cells, and values represent the percentage of CD8 T cells that are tetramer+. 7.5 and 9.4% of tetramer+ cells are of donor origin in the liver and lung, respectively. (E) Naive mice were thymectomized (thymx; n = 8) or sham operated (sham; n = 6). 45 d after PyV infection, spleens were analyzed for tetramer+ cells. The experiment was repeated twice with a combined p-value of 0.04.